Posted by Michael Wonder on 06 Sep 2023
Arcturus Therapeutics and CSL announce European Medicines Agency validates marketing authorisation application for ARCT-154 vaccine to prevent COVID-19
5 September 2023 - EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met.
Arcturus Therapeutics and CSL announced today that the EMA has validated the marketing authorisation application for ARCT-154, a next generation mRNA vaccine, for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
